TABLE 1.
Baseline clinical characteristics and clinical tests results of ATTRwt‐CM patients in this study
| Variables | All patients (n = 129) |
|---|---|
| Age at diagnosis, years | 78.5 ± 6.4 |
| Age at onset of symptom | 74.3 ± 6.4 |
| Male, n (%) | 110 (85%) |
| Past medical history | |
| Hypertension, n (%) | 69 (53%) |
| Diabetes mellitus, n (%) | 29 (22%) |
| Dyslipidaemia, n (%) | 43 (33%) |
| Atrial fibrillation, n (%) | 60 (47%) |
| Carpal tunnel syndrome, n (%) | 57 (n = 106, 54%) |
| Prior HF hospitalizations, n (%) | 53 (41%) |
| NYHA, n (%) | (n = 126) |
| I | 15 (12%) |
| II | 61 (48%) |
| III | 48 (38%) |
| IV | 2 (2%) |
| Blood testing | |
| hs‐cTnT, ng/mL | 0.056 (n = 123, 0.040–0.089) |
| BNP, pg/mL | 288 (181–464) |
| Sodium, mEq/L | 139.9 ± 3.0 |
| Potassium, mEq/L | 4.31 ± 0.42 |
| Creatinine, mg/dL | 1.09 (0.89–1.29) |
| eGFR, mL/min/1.73 m2 | 50.3 ± 14.9 |
| Haemoglobin, mg/dL | 13.4 (11.9–14.2) |
| Echocardiogram parameter | |
| LVDd mm | 42.4 ± 6.7 |
| LVDs, mm | 31.6 ± 6.7 |
| IVSd, mm | 15.7 ± 2.7 |
| LVPWd, mm | 15.7 ± 2.9 |
| LVEF, % | 53.2 (44.5–59.7) |
| LVEF < 50% | 53 (41%) |
| E/A ratio | 1.45 (n = 70, 0.76–2.50) |
| E/e′ ratio | 20.6 (16.1–25.7) |
| Electrocardiographic parameter | |
| Pacing rhythm, n (%) | 9 (7%) |
| V1–3 QS pattern, n (%) | 38 (n = 120, 32%) |
| Low voltage, n (%) | 43 (n = 120, 36%) |
| Bundle branch block, n (%) | 43 (n = 120, 36%) |
| CLBBB, n (%) | 14 (n = 120, 12%) |
| CRBBB, n (%) | 29 (n = 120, 24%) |
| Treatment | |
| RAS‐I, n (%) | 65 (50%) |
| MRA, n (%) | 42 (33%) |
| Beta‐blocker, n (%) | 38 (29%) |
| Diuretics, n (%) | 90 (70%) |
| PMI, n (%) | 15 (12%) |
| ICD, n (%) | 7 (5%) |
| CRT‐D/P, n (%) | 5 (4%) |
ATTRwt‐CM, wild‐type transthyretin amyloid cardiomyopathy; BNP, B‐type natriuretic peptide; CLBBB, complete left bundle branch block; CRBBB, complete right bundle branch block; CRT, cardiac resynchronization therapy; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; hs‐cTnT, high‐sensitivity cardiac troponin T; ICD, implantable cardioverter defibrillator; IVSd, interventricular septum diameter; LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVPWd, left ventricular posterior wall diameter; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PMI, pacemaker implantation; RAS‐I, renin–angiotensin system inhibitor.
Data are expressed as median [inter‐quartile range], mean ± standard deviation, or n (%).